Eli Lilly

Boston Scientific

UnitedHealth Group

Healthcare Stocks in Focus: Eli Lilly, UnitedHealth, Boston Scientific, Dow Jones and S&P 500 End Week with Modest Losses

Nvidia

Eli Lilly Doubles Down on AI: Is the Stock a Buy?

American Express

Unstoppable Stocks to Hold Forever: Eli Lilly, American Express, and Alphabet

Novo Nordisk

Eli Lilly vs. Novo Nordisk: Which Diabetes and Weight Loss Giant Reigns Supreme?

礼来

Eli Lilly's stock price: MACD Death Cross, Bollinger Bands Narrowing on 15min chart.

Catalyst<ul> <li>Most analysts rate LLY Buy or Strong Buy, showing broad institutional optimism.</li> <li>Recent technical signals such as Marubozu White and a Strong Bullish Hanging Man suggest emerging bullish momentum.</li></ul>Risk<ul> <li>Fund flow trends show net outflows in medium, large, and extra-large order sizes, indicating institutional caution.</li> <li>Technical indicators show that the market is in a volatile state, and the direction is not clear enough.</li></ul>

Key Factors

Eli Lilly shares fell 3.76% in pre-market trading on Jan. 16, 2026, due to the FDA delaying its review of a weight-loss drug to April 10. Eli Lilly acquired Ventyx Biosciences for $1.2 billion, marking its first M&A activity in 2026 and a strategic pivot into new market opportunities. Eli Lilly partnered with Nvidia to build an AI research lab, enhancing its drug discovery capabilities in a projected $15.2 billion AI pharmaceuticals market by 2030. Eli Lilly's Zepbound sales surpassed Novo Nordisk's Wegovy in the quarterly rankings, reflecting its growing dominance in the GLP-1 drug market. Eli Lilly's shares gained 39.2% in 2025 driven by the success of its weight-loss drugs, Zepbound and Mounjaro.

Recent Updates

LLY News